



OPEN ACCESS

EDITED AND REVIEWED BY
Donghoon Chung,
University of Louisville, United States

*CORRESPONDENCE

Li Xing
✉ xingli107@gmail.com

RECEIVED 13 January 2024
ACCEPTED 24 January 2024
PUBLISHED 31 January 2024

CITATION

Dong L and Xing L (2024) Editorial: The biological mechanism and health effect of co-infection with multiple pathogens. *Front. Cell. Infect. Microbiol.* 14:1370067. doi: 10.3389/fcimb.2024.1370067

COPYRIGHT

© 2024 Dong and Xing. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: The biological mechanism and health effect of co-infection with multiple pathogens

Li Dong^{1,2,3,4} and Li Xing^{1,2,3,4*}

¹Institutes of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China, ²Shanxi Provincial Key Laboratory of Medical Molecular Cell Biology, Shanxi University, Taiyuan, China, ³Shanxi Provincial Key Laboratory for Prevention and Treatment of Major Infectious Diseases, Taiyuan, China, ⁴The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan, China

KEYWORDS

co-infection, HIV, *Moraxella catarrhalis*, *Klebsiella pneumoniae*, *Mycobacterium tuberculosis*

Editorial on the Research Topic

The biological mechanism and health effect of co-infection with multiple pathogens

Co-infection by multiple pathogen species (*i.e.* viruses, bacteria, protozoa, fungal parasites, helminths *et al.*) is a ubiquitous phenomenon for infectious diseases, but the clinical outcomes and underlying mechanisms are complicated. HIV infection, tuberculosis, malaria (Boraschi *et al.*, 2008), hepatitis (Bosh *et al.*, 2018), leishmaniasis (Graepp-Fontoura *et al.*, 2023) and respiratory infections (Liu *et al.*, 2021) are always involved in co-infection globally. Co-infecting pathogens affect each other in multiple ways, such as competing for essential resources for living (Wale *et al.*, 2017), interfering with replication, or indirectly interacting against the host immune system (Ezenwa *et al.*, 2010), which can subsequently alter the pathogens transmission mode, disease aggressiveness and clinical symptoms and outcome. The status of co-infected patients can be complexed by overlapping drug toxicities and interactions, which challenges the optimal therapeutic regime. Co-infection at the population level can change the epidemic dynamics and determine the severity (Susi *et al.*, 2015). For example, secondary bacterial co-infection following infection of influenza viruses (Shrestha *et al.*, 2013), respiratory syncytial virus (RSV) (Lin *et al.*, 2022), or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Antuori *et al.*, 2023) contribute significantly to the loss of lives. So far, both experimental and mathematical models were applied to explore the mechanisms underlying the diverse clinical outcomes of co-infections. A number of factors including orders of pathogen arrival (Clay *et al.*, 2020), timings, and pairing may cooperatively or synergistically determine disease severity (Pinky *et al.*, 2023). The clinical needs and complexity of interactions between co-infecting pathogens necessitate further recording and analysis of co-infection under different circumstances. Herein, we still call the basic and clinical research papers focusing on the mechanism and consequences of virus or other pathogens co-infection, providing insightful information to facilitate the development of infectious disease treatment.

The current edition of *Frontiers in cellular and infection microbiology* features five articles highlighting the Rhinovirus (RV), HIV, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*-involved co-infections, respectively. One USA-based study used a co-infection model of human airway epithelium to test the effects of Rhinovirus infection on the existence of *Moraxella catarrhalis*. Another USA-based article describes the risk factors for co-infection with carbapenem-resistant *Klebsiella pneumoniae* and carbapenem-resistant *Pseudomonas aeruginosa* or *Acinetobacter baumannii*. Three articles address HIV-involved co-infections, where one cohort study was done by cooperation of Brazil and South Africa scientists to present the correlation of anemia and mycobacterial dissemination with the mortality of TB-associated HIV; one Chinese study explored the clearance of hepatitis B surface antigen during combined antiretroviral therapy of HIV/HBV (hepatitis B virus) co-infection; and one article reported a clinical case co-infected with HIV, HBV, HCV, and *Vibrio vulnificus*. *Moraxella catarrhalis* (*M. catarrhalis*) is causally associated with otitis media, sinusitis, and other chronic obstructive pulmonary disease. The abundance of *Moraxella catarrhalis* was observed previously to be increased during RV infection, but the mechanisms are still not clear. [Dissanayake et al.](#) established an *in vitro* model of differentiated bronchial epithelial cells and determined the effects of RV co-infection on *M. catarrhalis* cell association, abundance, and cellular responses. They inoculated RV-A16 to the apical surface of differentiated bronchial epithelium, and 2 hours later a clinical isolate of *M. catarrhalis* (strain MC14) was added. They found that RV-A16 infection caused significant cytotoxicity as indicated by LDH release and significantly increased cell-associated *M. catarrhalis*, but *M. catarrhalis* did not influence RV replication. These observed effects were specifically associated with the virulent RV strains (e.g. RV-A and RV-C types) ([Lee et al., 2012](#)), and appeared due to the RV-A16 infection-induced increase of expression level of carcinoembryonic antigen-related cell adhesion molecule (CEACAM), a key cellular receptor for outer membrane proteins UspA1 and UspA2 of *M. catarrhalis*. The results added new evidence and shed light to the previous notion that viral infection made the population susceptible to the secondary bacterial burden ([Shrestha et al., 2013](#); [Lin et al., 2022](#)).

By comparatively analyzing 86 patients with carbapenem-resistant *Klebsiella pneumoniae* (CRKP) mono-infection and 60 patients with co-infections of additional carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) or *Acinetobacter baumannii* (CRAB), [Sophonsri et al.](#) reports that respiratory tract instead of urinary tract was the predominant infection site for co-infected patients. Compared with CRKP mono-infection, co-infected patients usually have prior carbapenem exposure and history of pneumonia in the past year. Moreover, coinfecting patients often required direct intensive care unit (ICU) admission with a prolonged length of stay (median 15 vs 10 days). These results are informative for physician to formulate the checking and therapeutic treatment strategy.

The remaining three articles described the HIV-related co-infections and are especially meaningful for clinical practice.

[Araújo-Pereira et al.](#) studied 496 hospitalized adult people living with HIV (PLHIV) with CD4 count <350 cells/ μ L and high clinical suspicion of new tuberculosis (TB) infection enrolled in Cape Town (South Africa) between 2014-2016 and found that patients with severe anemia exhibited greater systemic inflammation, high levels of IL-8, IL-1RA and IL-6, which were associated with a higher *Mycobacterium tuberculosis* (*Mtb*) dissemination score and a higher risk of death. [Li et al.](#) performed a multivariate logistic analysis of 51 patients with HIV/HBV co-infections after initiating combined antiretroviral therapy (cART) and revealed that lower baseline CD4+ T cell levels (OR=6.633, P=0.012) and soluble programmed death-1 (sPD-1) level (OR=5.389, P=0.038) were independently associated with earlier rapid clearance of hepatitis B surface antigen (HBsAg) after cART initiation, which was also associated with the higher alanine aminotransferase abnormality rate and higher level of immune activation marker HLA-DR. [Zeng et al.](#) described diagnostic characters and successful treatment of a 48-year-old man co-infected with *Vibrio vulnificus* and multiple viruses including HIV, Hepatitis A and hepatitis B from Guangdong's coastal region in October, 2022. Instead of performing an amputation, the *Vibrio vulnificus*-infected limb was recovered by regular dressing changes, thorough debridement, wound closure, ongoing vacuum-sealing drainage (VSD), and local antibiotic irrigation. Taken together, these three articles provide novel perspectives on HIV-related co-infections and contribute to a better precise diagnosis and treatment to improve clinical care of co-infected patients.

Author contributions

LD: Writing – original draft, Writing – review & editing. LX: Conceptualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Supported by The Programme of Introducing Talents of Discipline to Universities (D21004); Four “batches” innovation project of invigorating medical through science and technology of Shanxi province (2023XM015); Key Research and development program of Shanxi province (202102130501009).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Antuori, A., Giménez, M., Linares, G., and Cardona, P. J. (2023). Characterization of respiratory bacterial co-infection and assessment of empirical antibiotic treatment in patients with COVID-19 at hospital admission. *Sci. Rep.* 13 (1), 19302. doi: 10.1038/s41598-023-46692-x
- Borachi, D., Alemayehu, M. A., Aseffa, A., Chiodi, F., Chisi, J., Del Prete, G., et al. (2008). Immunity against HIV/AIDS, Malaria, and Tuberculosis during Co-Infections with Neglected Infectious Diseases: Recommendations for the European Union Research Priorities. *PLoS Negl. Trop. Dis.* 2 (6), e255. doi: 10.1371/journal.pntd.0000255
- Bosh, K. A., Coyle, J. R., Hansen, V., Kim, E. M., Speers, S., Comer, M., et al. (2018). HIV and viral hepatitis co-infection analysis using surveillance data from 15 US states and two cities. *Epidemiol. Infect.* 146, 920–930. doi: 10.1017/S0950268818000766
- Clay, P. A., Duffy, M. A., and Rudolf, V. H. W. (2020). Within-host priority effects and epidemic timing determine outbreak severity in co-infected populations. *Proc. R. Soc. B-Biological Sci.* 287 (1922), 20200046. doi: 10.1098/rspb.2020.0046
- Ezenwa, V. O., Etienne, R. S., Luikart, G., Beja-Pereira, A., and Jolles, A. E. (2010). Hidden consequences of living in a wormy world: nematode-induced immune suppression facilitates tuberculosis invasion in african buffalo. *Am. Nat.* 176, 613–624. doi: 10.1086/656496
- Graepff-Fontoura, I., Barbosa, D. S., Fontoura, V. M., Guerra, R. N. M., Melo, S. D., Fernandes, M. N. D., et al. (2023). Visceral leishmaniasis and HIV co-infection in Brazil: epidemiological profile and spatial patterns. *Trans. R. Soc. Trop. Med. Hygiene* 117, 260–270. doi: 10.1093/trstmh/trac093
- Lee, W. M., Lemanske, R. F., Evans, M. D., Vang, F., Pappas, T., Gangnon, R., et al. (2012). Human rhinovirus species and season of infection determine illness severity. *Am. J. Respir. Crit. Care Med.* 186, 886–891. doi: 10.1164/rccm.201202-0330OC
- Lin, H. C., Liu, Y. C., Hsing, T. Y., Chen, L. L., Liu, Y. C., Yen, T. Y., et al. (2022). RSV pneumonia with or without bacterial co-infection among healthy children. *J. Formosan Med. Assoc.* 121, 687–693. doi: 10.1016/j.jfma.2021.08.012
- Liu, Y. Z., Ling, L. W., Wong, S. H., Wang, M. H., Fitzgerald, J. R., Zou, X., et al. (2021). Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. *Eclinicalmedicine* 37, 100955. doi: 10.1016/j.eclinm.2021.100955
- Pinky, L., Deaguero, J. R., Remien, C. H., and Smith, A. M. (2023). How interactions during viral-viral co-infection can shape infection kinetics. *Viruses-Basel* 15 (6), 1303. doi: 10.3390/v15061303
- Shrestha, S., Foxman, B., Weinberger, D. M., Steiner, C., Viboud, C., and Rohani, P. (2013). Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. *Sci. Trans. Med.* 5 (191), 191ra84. doi: 10.1126/scitranslmed.3005982
- Susi, H., Barrès, B., Vale, P. F., and Laine, A. L. (2015). Co-infection alters population dynamics of infectious disease. *Nat. Commun.* 6, 5975. doi: 10.1038/ncomms6975
- Wale, N., Sim, D. G., and Read, A. F. (2017). A nutrient mediates intraspecific competition between rodent malaria parasites. *Proc. R. Soc. B-Biological Sci.* 284 (1859), 20171067. doi: 10.1098/rspb.2017.1067